The association study of polymorphisms in DAT, DRD2, and COMT genes and acute extrapyramidal adverse effects in male schizophrenic patients treated with haloperidol

Journal of Clinical Psychopharmacology

Volumn 33, Issue 5, 2013, Pages 593-599

  Zivković, Maja ^a   Mihaljević Peles, Alma ^b   Bozina, Nada ^c   Sagud, Marina ^a   Nikolac Perkovic, Matea ^d   Vuksan Cusa, Bjanka ^a   Muck Seler, Dorotea ^d  

^a Psychiatric Hospital Vrap e   (Croatia)

^b UNIVERSITY OF ZAGREB   (Croatia)

^c KBC Zagreb   (Croatia)

^d RUDER BO KOVI INSTITUTE   (Croatia)

Author keywords

[No Author keywords available]

Indexed keywords

CATECHOL METHYLTRANSFERASE; DOPAMINE 2 RECEPTOR; DOPAMINE TRANSPORTER; HALOPERIDOL; SLC6A PROTEIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; DRUG SAFETY; EXTRAPYRAMIDAL SYMPTOM; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL PATIENT; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; SCHIZOPHRENIA; SIMPSON-ANGUS SCALE; SINGLE NUCLEOTIDE POLYMORPHISM; VARIABLE NUMBER OF TANDEM REPEAT;

ACUTE DISEASE; ADULT; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; CATECHOL O-METHYLTRANSFERASE; CHI-SQUARE DISTRIBUTION; CROATIA; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HALOPERIDOL; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MINISATELLITE REPEATS; MULTIVARIATE ANALYSIS; ODDS RATIO; PHARMACOGENETICS; PHENOTYPE; POLYMORPHISM, GENETIC; RECEPTORS, DOPAMINE D2; RISK FACTORS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SEX FACTORS; TIME FACTORS; YOUNG ADULT;

EID: 84883790639     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e31829abec9     Document Type: Article

References (53)

1. Andreasen NC, Carpenter WT Jr, Kane JM, et al. Remission in schizophrenia: Proposed criteria and rational, for consensus. Am J Psychiatry. 2005;162:441-449
2. Emsley R, Chiliza B, Asmal L, et al. The concepts of remission and recovery in schizophrenia. Curr Opin Psychiatry. 2011;24:114-121
3. Gorwood P, Peuskens J;, European Group on Functional Outcomes, Remission in Schizophrenia. Setting new standards in schizophrenia outcomes: Symptomatic remission 3 years before versus after the Andreasen criteria. Eur Psychiatry. 2012;27:170-175
4. Casey DE. Neuroleptic-induce acute extrapyramidal syndromes and tardive dyskinesia. Psychiatr Clin North Am. 1993;16:589-610
5. Kapur S, Zipursky R, Jones C, et al. Relationship between dopamine (D(2)) occupancy, clinical response and side effects, a double-blind PET study of first-episode schizophrenia. Am J Psychiatry. 2000;157:514-520
6. Lafuente A, Bernardo M, Mas S, et al. Polymorphism of dopamine D2 receptor (TaqIB, TaqIB, and-141C Ins/Del) and dopamine degradation enzyme (COMT G158A, A-278G) genes and extrapyramidal symptoms in patients with schizophrenia and bipolar disorders. Psychiatry Research. 2008;161:131-141
7. Miyamoto S, Duncan GE, Marx CE, et al. Treatment of schizophrenia; a critical review of pharmacology and mechanism of action of antipsychotic drugs. Mol Psychiatry. 2005;10:79-104
8. Lewis R. Typical and atypical antipsychotics in adolescent schizophrenia: Efficacy, tolerability, and differential sensitivity to extrapyramidal symptoms. Can J Psychiatry. 1998;43:596-604
9. Dayalu P, Chou KL. Antipsychotic-induced extrapyramidal symptoms and their management. Expert Opin Pharmacother. 2008;9:1451-1462
10. Farde L, Nordstron AL,Wiesel FA, et al. Positron emission tomographic analysis of central D1 and D2 dopamine receptors occupancy in patients treated with classical neuroleptics and clozapine. Relations to extrapyramidal side effects. Arch Gen Psychiatry. 1992;49:538-544
11. Remington G, Kapur S. D2 and 5HT2 receptor effects of antipsychotic; bridging basic and clinical findings using PET. J Clin Psychiatry. 1999;60:15-19
12. Zhang JP, Malhotra AK. Pharmacogenetics and antipsychotics: Therapeutic efficacy and side effects prediction. Expert Opin Metab Toxicol. 2011;7:9-39
13. Mihaljevic-Peles A, Sagud M, Bozina N, et al. Pharmacogenetics and antipsychotics in the light of personalized pharmacotherapy. Psychiatr Danub. 2010;22:335-337
14. Thompson J, Thomas N, Singleton A, et al. D2 dopamine receptor gene (DRD2) Taq1A polymorphism: Reduced dopamine D2 receptor binding in the human striatum associated with the A1 allele. Pharmacogenetics. 1997;7:479-484
15. Pohjalainen T, Rinne JO, Nagren K, et al. The A1 allele of the human D2 dopamine receptor gene predicts low D2 receptor availability in health volunteers. Mol Psychiatry. 1998;3:256-260
16. Jönsson EG, Nothen MM, Grunhage F, et al. Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers. Mol Psychiatry. 1999;4:290-296
17. Zai CC, De Luca V, Hwang RW, et al. Meta-Analysis of two dopamine D2 receptor gene polymorphisms with tardive dyskinesia in schizophrenia patients. Mol Psychiatry. 2007;12:794-795
18. Bakker PR, van Harten PN, van Os J. Antipsychotic-induced tardive dyskinesia and polymorphic variations in COMT, DRD2, CYP1A2 and MnSOD genes: A meta-Analysis of pharmacogenetics interactions. Mol Psychiatry. 2008;13:544-556
19. Mihara K, Suzuki A, Kondo T, et al. No relationship between TaqIA polymorphism of dopamine D2 receptor gene and extrapyramidal adverse effects of selective D2 antagonists, bromperidol and nemonapride in schizophrenia: A preliminary study. Am J Med Genet. 2000;96:422-424
20. Kaiser R, Treblay PB, Klufmoller F, et al. Relationship between adverse effects of antipsychotic treatment and dopamine D2 receptor polymorphism in patients with schizophrenia. Mol Psychiatry. 2002;7:695-705
21. Gunes A, Scordo MG, Jaanson P, et al. Serotonin and dopamine receptor gene polymorphisms and risk of extrapyramidal side effects in perphenazine-Treated schizophrenic patients. Psychopharmacology. 2007;190:497-484
22. Guzey C, Scordo MG, Spina E, et al. Antipsychotic-induced extrapyramidal symptoms in patients with schizophrenia: Associations with dopamine and serotonin receptor and transporter polymorphisms. Eur J Clin Pharmacol. 2007;63:233-241
23. Costa A, Riedel M, Müller U, et al. Relationship between SLC6A3 genotype and striatal dopamine transporter availability: A meta-Analysis of human single photon emission computed tomography studies. Synapse. 2011;65:998-1005
24. Georgieva L, Dimitrova A, Nikolov I, et al. Dopamine transporter gene (DAT1) VNTR polymorphism in major psychiatric disorders: Family-based association study in the Bulgarian population. Acta Psychiatr Scand. 2002;105:396-399
25. Vandenberg DJ, Thompson MD, Cook EH, et al. Human dopamine transporter gene: Coding region conservation among normal, Tourrette's disorder, alcohol dependence and attention-deficit hyperactivity disorder population. Mol Psychiatry. 2000;5:283-292
26. Lafuente A, Bernardo M, Mas S, et al. Dopamine transporter (DAT) genotype (VNTR) and phenotype in extrapyramidal symptoms induced by antipsychotics. Schizophr Res. 2007;90:115-122
27. Gasso P, Mas S, Crescenti A, et al. Lack of association between antipsychotic-induced extrapyramidal symptoms and polymorphisms in dopamine metabolism and transport gene. Psychiatry Res. 2010;175:173-175
28. Xu M, Xing Q, Li S, et al. Pharmacogenetics effects of dopamine transporter gene polymorphisms on response to chlorpromazine and clozapine and extrapyramidal syndrome in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34:1026-1032
29. Lotta T, Vidgren J, Tilgmann C, et al. Kinetics of human soluble and membrane bound catechol-O-methyltransferase: A revised mechanism and description of the thermolabile variant of the enzyme. Biochemistry. 1995;34:4202-4210
30. Kay SR, Fiszbein A, Opler LA. Positive and negative symptom scale (PANNS) for schizophrenia. Schizophr Bull. 1998;13:21-76
31. Simpson GM, Angus JW. A rating scale for extra-pyramidal side effects. Acta Psychiatry Scand. 1970;212:11-19
32. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acid Res. 1988;16:1215
33. Grandy DK, Zhang Y, Civelli O. PCR detection of the TaqA RFLP at the DRD2 locus. Hum Mol Genet. 1993;2:2197
34. Chen WJ, Chen CH, Huang J, et al. Genetic polymorphisms of the promoter region of dopamine D2 receptor and dopamine transporter genes and alcoholism among four aboriginal groups and Han Chinese in Taiwan. Psychiatr Genet. 2001;11:187-195
35. Vandenberg DJ, Persico AM, Hawkins AL, et al. Human dopamine transporter gene (DAT1) maps to chromosome 5p15.3 and displays a VNTR. Genomics. 1992;14:1104-1106
36. Lin JJ, Yueh KC, Chang DC, et al. The homozygote 10-copy genotype of variable number tandem repeat dopamine transporter gene may confer protection against Parkinson's disease for male, but not to female patients. J Neurol Sci. 2003;209:87-92
37. Kasten M, Brüggemann N, König IR, et al. Risk for antipsychotic-induced extrapyramidal symptoms: Influence of family history and genetic susceptibility. Psychopharmacology. 2011;214:729-736
38. Pierre JM. Extrapyramidal symptoms with atypical antipsychotics: Incidence, prevention and management. Drug Saf. 2005;28:191-208
39. Kane JM, Cohen M, Zhao J, et al. Efficacy and safety of asenapine in a placebo-And haloperidol-controlled trial in patients with acute exacerbation of schizophrenia. J Clin Psychopharmacol. 2010;30:106-115
40. Gamma F, Faraone SV, Glatt SJ, et al. Meta-Analysis shows schizophrenia is not associated with the 40-base pair repeat polymorphism of the dopamine transporter gene. Schizophr Res. 2005;731:55-58
41. Greenwood TA, Kelsoe Jr. Promoter and intronic variants affect the transcriptional regulation of the human dopamine transporter gene. Genomics. 2003;82:511-520
42. Mill J, Asherson P, Craig I, et al. Transient expression analysis of allelic variants of a VNTR in the dopamine transporter gene (DAT1). BMC Genet. 2005;6:3
43. Miller GM, Madras BK. Polymorphisms in the 3'-untranslated region of human and monkey dopamine transporter genes affect reporter gene expression. Mol Psychiatry. 2002;7:44-55
44. Fuke S, Suo S, Takahashi N, et al. The VNTR polymorphism of the human dopamine transporter (DAT1) gene affects gene expression. Pharmacogenomics J. 2001;1:152-156
45. Carr DB, Sesack SR. Projections from the rat prefrontal cortex to the ventral tegmental area: Target specificity in the synaptic associations with mesoaccumbens and mesocortical neurons. J Neuroscience. 2000;20:3864-3873
46. Carlsson A. A paradigm shift in brain research. Science. 2001;294:1021-1024
47. Meshul CK, Stallbaumer RK, Taylor B, et al. Haloperidol-induced morphological changes in striatum are associated with glutamate synapses. Brain Res. 1994;648:181-195
48. Comings DE, MacMurray JM. Molecular heterosis: A review. Mol Genet Metab. 2000;71:19-31
49. Laruelle M, Gele r J, Innis RB. D2 receptors binding potential is not affected by Taq1 polymorphism at the D2 receptor gene. Mol Psychiatry. 1998;3:261-265
50. Kaiser R, Tremblay P-B, Klufmöller I, et al. Relationship between adverse effects of antipsychotic treatment and dopamine D2 receptor polymorphisms in patients with schizophrenia. Mol Psychiatry. 2002;7:695-705
51. Crescenti A, Mas S, Gasso P, et al. Cyp2d6&z.ast;3, &z.ast;4, &z.ast;5 and &z.ast;6 polymorphisms and antipsychotic-induced extrapyramidal side-effects in patients receiving antipsychotic therapy. Clin Exp Pharmacol Physiol. 2008;35:807-811
52. Scordo MG, Spina E, Romeo P, et al. CYP2D6 genotype and antipsychotic-induced extrapyramidal side effects in schizophrenia patients. Eur J Clin Pharmacol. 2000;56:679-683
53. Gilham D, Cairns W, Paine M, et al. Metabolism of MPTP by cytochrome P4502D6 and the demonstration of 2D6 mRNA in human foetal and adult brain by in situ hybridization. Xenobiotica. 1997;27:111-125